These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24118860)

  • 1. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
    Florez H; Temprosa MG; Orchard TJ; Mather KJ; Marcovina SM; Barrett-Connor E; Horton E; Saudek C; Pi-Sunyer XF; Ratner RE; Goldberg RB;
    Diabetes Obes Metab; 2014 Apr; 16(4):326-33. PubMed ID: 24118860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.
    Goldberg RB; Temprosa M; Haffner S; Orchard TJ; Ratner RE; Fowler SE; Mather K; Marcovina S; Saudek C; Matulik MJ; Price D;
    Diabetes Care; 2009 Apr; 32(4):726-32. PubMed ID: 19171717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
    Orchard TJ; Temprosa M; Goldberg R; Haffner S; Ratner R; Marcovina S; Fowler S;
    Ann Intern Med; 2005 Apr; 142(8):611-9. PubMed ID: 15838067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
    Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
    Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of body size and shape to the development of diabetes in the diabetes prevention program.
    Diabetes Prevention Program Research Group
    Obesity (Silver Spring); 2006 Nov; 14(11):2107-17. PubMed ID: 17135629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a Metabolic Syndrome Severity
    DeBoer MD; Filipp SL; Gurka MJ
    Diabetes Care; 2018 Nov; 41(11):2421-2430. PubMed ID: 30275282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.
    Herman WH; Pan Q; Edelstein SL; Mather KJ; Perreault L; Barrett-Connor E; Dabelea DM; Horton E; Kahn SE; Knowler WC; Lorenzo C; Pi-Sunyer X; Venditti E; Ye W;
    Diabetes Care; 2017 Dec; 40(12):1668-1677. PubMed ID: 29021207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.
    Goldberg RB; Mather K
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2077-90. PubMed ID: 22895669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
    ; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
    Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults.
    Malin SK; Nightingale J; Choi SE; Chipkin SR; Braun B
    Obesity (Silver Spring); 2013 Jan; 21(1):93-100. PubMed ID: 23505172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
    Ratner R; Goldberg R; Haffner S; Marcovina S; Orchard T; Fowler S; Temprosa M;
    Diabetes Care; 2005 Apr; 28(4):888-94. PubMed ID: 15793191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2).
    Ramachandran A; Arun N; Shetty AS; Snehalatha C
    Diabetes Care; 2010 Oct; 33(10):2164-8. PubMed ID: 20519663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
    Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile.
    Heald AH; Knapman H; Nair S; Chambers T; Radford D; Rushton T; Anderson SG
    Prim Care Diabetes; 2012 Oct; 6(3):213-9. PubMed ID: 22560663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
    Ratner RE; Christophi CA; Metzger BE; Dabelea D; Bennett PH; Pi-Sunyer X; Fowler S; Kahn SE;
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4774-9. PubMed ID: 18826999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab).
    Gagnon C; Lu ZX; Magliano DJ; Dunstan DW; Shaw JE; Zimmet PZ; Sikaris K; Ebeling PR; Daly RM
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1953-61. PubMed ID: 22442263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
    Tuomilehto J; Lindström J; Hellmich M; Lehmacher W; Westermeier T; Evers T; Brückner A; Peltonen M; Qiao Q; Chiasson JL
    Diabetes Res Clin Pract; 2010 Feb; 87(2):267-74. PubMed ID: 20022651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.